A multiple imputation method for sensitivity analyses of time-to-event data with possibly informative censoring

Journal of Biopharmaceutical Statistics

Volumn 24, Issue 2, 2014, Pages 229-253

  Zhao, Yue ^a   Herring, Amy H ^b   Zhou, Haibo ^b   Ali, Mirza W ^c   Koch, Gary G ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Multiple imputation; Sensitivity analysis; Time to event data2

Indexed keywords

ARTICLE; BIPOLAR DISORDER; BOOTSTRAPPING; CENSORSHIP; EFFECT SIZE; EXPLANATORY VARIABLE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MULTIPLE IMPUTATION METHOD; OUTCOME ASSESSMENT; PATIENT INFORMATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANK SUM TEST; SENSITIVITY ANALYSIS; SURVIVAL RATE; TIME TO EVENT DATA; TREATMENT WITHDRAWAL; CLINICAL TRIAL (TOPIC); STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; TIME;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 84896772250     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2013.860769     Document Type: Article

References (28)

1. Brown, J. B. W., Hollander, M., Korwar, R. M. (1974). Nonparametric tests of independence for censored data, with applications to heart transplant studies. In Proschan, F., Serfling, R. J., editors, In Reliability and Biometry: Statistical Analysis of Lifelength. Philadelphia, PA: SIAM, pp. 327-354.
2. Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O. P., Montgomery, P., Ascher, J., Paska, W., Earl, N., DeVeaugh-Geiss, J., Lamictal 605 Study Group. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 64(9):1013-1024. (Pubitemid 37158246)
3. Committee for Medicinal Products for Human Use. CHMP (2010). Guideline on Missing data in Confirmatory Clinical Trials (EMA/CPMP/EWP/1776/99). London: CHAMP.
4. Cox, D. R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society. Series B (Methodological) 34(2):187-220.
5. Flyer, P. A. (2009). Discussion: "Incomplete data in clinical studies: Analysis, sensitivity, and sensitivity analysis" by Geert Molenberghs. Drug Information Journal 43(4):437-439.
6. Flyer, P., Hirman, J. (2009). Missing data in confirmatory clinical trials. Journal of Biopharmaceutical Statistics 19(6):969-979.
7. Gehan, E. A. (1965). A generalized wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203-223.
8. Heitjan, D. F. (1994) Ignorability in general incomplete-data models. Biometrika 81 (4): 701-708.
9. Horton, N. J., Lipsitz, S. R. (2001). Multiple imputation in practice: Comparison of software packages for regression models with missing variables. The American Statistician 55(3):244-254. (Pubitemid 33318033)
10. Kaplan, E. L., Meier, P. (1958). Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53:457-481.
11. Little, R. J. A., Rubin, D. B. (2002). Statistical Analysis with Missing Data. New York, NY: John Wiley & Sons, Inc. Little, R. J. A., Yau, L. (1996). Intent-to-treat analysis for longitudinal studies with dropouts. Biometrics, 52(4):11324-1333.
12. Mallinckrodt, C. H., Lane, P. W., Schnell, D., Peng, Y., Mancuso, J. P. (2008). Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Information Journal 42(4):303-319.
13. Mantel, N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 50:163-170.
14. National Research Council, Panel on Handling Missing Data in Clinical Trials. (2010). The Preventing and treatment of Missing Data in Clinical Trial. Washington, DC: National Academies Press. ISBN 9780309158145. Available at: www.nap.eduopenbook.php? record-id=12955.
15. Permutt, T., Pinheiro, J. (2009). Editorial: Dealing with the missing data challenges in clinical trials. Drug Information Journal 43(4):403-408.
16. Roger, J. H. (2008). Sensitivity Analysis for Longitudinal Studies With Withdrawals in Practice. GlaxoSmithKline, 2008 U.S. Biostatistics Annual Conference, Research Triangle Park, NC; November.
17. Rothmann, M. D., Koti, K., Lee, K. Y., Lu, H. L., Shen, Y. L. (2009). Missing data in biologic oncology products. Journal of Biopharmaceutical Statistics 19(6):1074-1084.
18. Ruan, P. K., Gray, R. J. (2008). Sensitivity analysis of progression-free survival with dependent withdrawal. Statistics in Medicine 27(8):1180-1198. (Pubitemid 351395450)
19. Rubin, D. B. (1987). Multiple Imputation for Nonresponse in Survey New York, NY: John Wiley & Sons.
20. Rubin, D. B., Schenker, N. (1991). Multiple imputations in health-care database: An overview and some applications. Statistics in Medicine 10(4):585-598.
21. Schafer, J. L. (1999). Multiple imputation: A primer. Statistical Methods in Medical Research 8(1):3-15. (Pubitemid 29222784)
22. Scharfstein, D. O., Robins, J. M. (2002). Estimation of the failure time distribution in the presence of informative censoring. Biometrika 89(3):617-634. (Pubitemid 41311969)
23. Siannis, F., Copas, J., Lu, G., (2005). Sensitivity analysis for informative censoring in parametric survival models. Biostatistics 6(1):77-91. (Pubitemid 41240371)
24. Taylor, J. M. G., Murray, S., Hsu, C.-H. (2002). Survival estimation and testing via multiple imputation. Statistics and Probability Letters 58(3):221-232.
25. Walton, M. K. (2009). Addressing and advancing the problem of missing data. Journal of Biopharmaceutical Statistics 19(6):945-956.
26. Wittes, J. (2009). Missing inaction: Preventing missing outcome data in randomized clinical trials. Journal of Biopharmaceutical Statistics 19(6):957-968.
27. Yan, X., Lee, S., Li, N. (2009). Missing data handling methods in medical device clinical trials. Journal of Biopharmaceutical Statistics 19(6):1085-1098.
28. Zhang, J. (2009). Sensitivity analysis of missing data: Case studies using model-based mulitple imputation. Drug Information Journal 43:475-484.